Advanced search
Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 42, 2018 - Issue 5-6
Submit an article Journal homepage
427
Views
19
CrossRef citations to date
0
Altmetric
Short Communication

Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition

Efthymia VlachakiAdult Thalassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece;
,
Eleni GavriilakiHaematology Department, Bone Marrow Transplantation Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; Correspondence[email protected]
,
Katerina KafantariAdult Thalassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece;
,
Despoina AdamidouBlood Bank, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece;
,
Dimitris TsitsikasHaemoglobinopathy Service, Homerton University Hospital National Health Service Foundation Trust, London, UK;
,
Eleni ChasapopoulouBlood Bank, AHEPA Hospital, Thessaloniki, Greece
,
Achilles AnagnostopoulosHaematology Department, Bone Marrow Transplantation Unit, G. Papanicolaou Hospital, Thessaloniki, Greece;
&
Apostolos TsapasAdult Thalassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece;
show all
Pages 339-341 | Received 22 Sep 2018, Accepted 20 Oct 2018, Published online: 09 Jan 2019

References

  • Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746–753.
  • de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801–807.
  • Jasinski S, Glasser CL. Catastrophic delayed hemolytic transfusion reaction in a patient with sickle cell disease without alloantibodies: case report and review of literature. J Pediatr Hematol/Oncol. 2018 Aug 31. DOI:10.1097/MPH.0000000000001307. [Epub ahead of print].
  • Boonyasampant M, Weitz IC, Kay B, et al. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015;55(10):2398–2403.
  • Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062–1064.
  • Chonat S, Quarmyne MO, Bennett CM, et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018;103(10):e483–e485. DOI:10.3324/haematol.2018.194670
  • Gavriilaki E, Mainou M, Christodoulou I, et al. In vitro evidence of complement activation in patients with sickle cell disease [Letter]. Haematologica. 2017;102(12):e481–e482.
  • Gavriilaki E, Christodoulou I, Koravou E-E, et al. Pre- and post-transfusion complement activation in transfusion-dependent β-thalassaemia. HemaSphere. 2018;2(5):e58. DOI:10.1097/hs9.0000000000000058
  • Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847.
  • Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–2181.
  • Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384–388.
  • Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol. 2009;2(2):111–115.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.